No connection

Search Results

ABBV vs MBAI

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
MBAI
Check-Cap Ltd.
BEARISH
Price
$1.80
Market Cap
$13.1M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
ABBV
163.63
MBAI
--
Forward P/E
ABBV
15.42
MBAI
--
P/B Ratio
ABBV
-146.66
MBAI
2.8
P/S Ratio
ABBV
6.5
MBAI
--
EV/EBITDA
ABBV
15.27
MBAI
-2.46

Profitability

Gross Margin
ABBV
71.46%
MBAI
0.0%
Operating Margin
ABBV
35.5%
MBAI
0.0%
Profit Margin
ABBV
4.0%
MBAI
0.0%
ROE
ABBV
137.96%
MBAI
-130.12%
ROA
ABBV
9.59%
MBAI
-20.82%

Growth

Revenue Growth
ABBV
9.1%
MBAI
--
Earnings Growth
ABBV
-88.7%
MBAI
--

Financial Health

Debt/Equity
ABBV
--
MBAI
0.04
Current Ratio
ABBV
0.72
MBAI
0.71
Quick Ratio
ABBV
0.47
MBAI
0.71

Dividends

Dividend Yield
ABBV
3.05%
MBAI
--
Payout Ratio
ABBV
490.15%
MBAI
0.0%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
MBAI BEARISH

MBAI exhibits severe financial distress, anchored by a weak Piotroski F-Score of 3/9 and a critical lack of revenue. The company has reported losses for 25 consecutive quarters, with a devastating ROE of -130.12% and a Current Ratio of 0.71, indicating an inability to cover short-term liabilities. While the 1-year price performance shows a speculative rally, the underlying fundamentals are non-existent, and the absence of an Altman Z-Score or Graham Number reflects a lack of stable equity or earnings to support a valuation.

Strengths
Very low Debt/Equity ratio (0.04)
Recent reduction in the magnitude of quarterly losses
Strong 1-year price momentum (+175.7%)
Risks
Severe liquidity risk with a Current Ratio of 0.71
Chronic lack of profitability over 25 consecutive quarters
Zero reported profit and operating margins

Compare Another Pair

ABBV vs MBAI: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and Check-Cap Ltd. (MBAI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile